General Information of Drug (ID: DM3F5E0)

Drug Name
TEI-6122 Drug Info
Synonyms TFC-612
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
6439638
CAS Number
CAS 83058-69-9
TTD Drug ID
DM3F5E0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bimatoprost DMX0E5B Alopecia ED70 Approved [3]
Unoprostone DMXNR04 Glaucoma/ocular hypertension 9C61 Approved [4]
Iclaprim DM7YNV9 Bacterial infection 1A00-1C4Z Phase 3 [5]
JB991 DMKU6MW Skin infection 1F28-1G0Z Phase 2 [6]
Taprostene DMA4WY5 Thrombosis DB61-GB90 Discontinued in Phase 3 [7]
ZD-4953 DM5UCHW Pain MG30-MG3Z Discontinued in Phase 2 [8]
YP-009 DMPXLG2 Solid tumour/cancer 2A00-2F9Z Terminated [9]
YP-008 DM2N76V Psoriasis vulgaris EA90 Terminated [10]
IP-1200 DMIX7CP Erectile dysfunction HA01.1 Investigative [11]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin receptor (PTGR) TT9B4N3 NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003140)
2 The effect of a synthetic 7-thiaprostaglandin E1 derivative, TEI-6122, on monocyte chemoattractant protein-1 induced chemotaxis in THP-1 cells.. Br J Pharmacol. 1995 October; 116(4): 2298-2302.
3 Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95.
4 Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504.
5 Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677.
6 US patent application no. 2006,0041,016, Composition and method for the treatment of psoriasis.
7 Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse. J Cardiovasc Pharmacol. 2004 Jun;43(6):795-807.
8 WO patent application no. 2013,1675,82, Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease.
9 YP 009 York Pharma pc preclinical, UK(cancer), R & D Focus Drug News, November 12, 2007
10 CA patent application no. 841416, Method of selecting therapeutic indications.
11 Clinical pipeline report, company report or official report of Immunologic.